|
Tocilizumab para el tratamiento de la artritis reumatoidea [Tocilizumab for the treatment of rheumatoid arthritis] |
Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Oubiña M |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Oubiña M. Tocilizumab para el tratamiento de la artritis reumatoidea. [Tocilizumab for the treatment of rheumatoid arthritis] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N° 319. 2013 Authors' objectives To assess the available evidence on the efficacy, safety and coverage related aspects regarding the use of tocilizumab in patients with RA. Authors' conclusions There is high quality methodological evidence on the efficacy of tocilizumab therapy in patients with moderate to severe RA, however, there is not adequate evidence on its efficacy compared to other biological agents. Only one comparative study showed that in patients who cannot receive methotrexate, tocilizumab is clinically and statistically more efficacious as monotherapy when compared with adalimumab monotherapy, however, there are no other RCTs assessing its efficacy versus other biological agents, and studies based on indirect comparisons suggest that it is similar to etanercept. Some international guidelines consider its use as another alternative in case of inadequate response to DMARDs, other guidelines only consider it in case of anti-TNF or biological agent failure. In view of this, the decision regarding coverage will depend on the relative cost of tocilizumab versus the other therapies. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoids Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32014000243 Date abstract record published 28/01/2014 |
|
|
|